AAX Biotech to Showcase Pioneering Antibody Therapies at BIO-Europe Spring 2026
AAX Biotech will attend the BIO-Europe Spring conference in Lisbon in March 2026. The company will showcase its advanced Seqitope® and Opti-mAb® platforms, redefining antibody therapy development.
Innovative biotechnology firm AAX Biotech is heading to Lisbon in March 2026 to participate in the esteemed BIO-Europe Spring conference. The event, scheduled from March 23–25, will provide a platform for AAX Biotech to present its revolutionary advancements in antibody therapeutics.
Maria L. Knudsen, AAX Biotech's Chief Business Officer (CBO), will represent the company. She aims to connect with both current and prospective pharmaceutical collaborators, fostering relationships within the global biopharma community, and discussing the potential of the company's pioneering technologies, the Seqitope® and Opti-mAb® platforms.
These platforms are anticipated to redefine the next generation of antibody-based treatments. AAX Biotech's presence underscores its commitment to innovation and collaboration in advancing the field. The company invites all interested parties to meet them in Lisbon to discuss potential partnerships and the future of biotherapeutic technology.